By Brad Dress June 15, 2022 At least two-thirds of older Americans see health care costs as a financial burden, according to a new West Health-Gallup survey published Wednesday. About 24 percent of Americans ages 50-64 say health care costs are a major financial burden, compared to 48 percent who say the costs are a minor burden,… Read more »
By Nicole Willcoxon, Ph.D June 15, 2022 WASHINGTON, D.C. — The health problems Americans start facing when they reach 50 years of age are compounded when the high cost of healthcare prevents them from seeking treatment, taking their prescriptions or leading an otherwise healthy lifestyle. A survey of U.S. adults conducted by West Health and… Read more »
By Sen. Bernie Sanders May 12, 2022 The United States has the most dysfunctional, inefficient, bureaucratic and expensive health care system in the world. That’s not just what I believe. That’s what the American people know to be true. According to a March 2022 survey by Gallup and West Health, an estimated 93 percent of American adults feel… Read more »
Medicare also has precedent on its side regarding coverage of other medical products developed for Alzheimer’s patients. Aduhelm isn’t the first medical product associated with Alzheimer’s disease that has been subject to a CED, said Sean Dickson, director of health policy at the West Health Policy Center.
Around 112 million Americans have trouble paying for health care, while more than 90 percent of the country believes it is not worth the cost. The data was collected by Gallup and West Health through the Healthcare Affordability Index and Healthcare Value Index
Aduhelm’s price drop in December was a windfall for providers in the first quarter of this year because Medicare was still reimbursing them the previous price plus the add-on payment, according to Sean Dickson, director of health policy for West Health.
CMS should subtract rebates and pharmacy fees from the prices that Medicare beneficiaries pay for drugs, but it should count them when calculating Part D coverage phases, according to West Health Policy Center.
The venture will eventually be self-sustaining, said Shelley Lyford, vice chair of Civica Rx’s board. It will initially produce enough insulin to cover about 30% of the market.
The consortium’s nonprofit company, Civica Rx, said Thursday it plans to manufacture and sell generic versions of insulin at no more than $30 per vial and $55 for five injector-pen cartridges, a fraction of list prices that currently range from $125 to more than $500.
Non-profit drugmaker Civica said on Thursday it expects to launch lower-cost versions of insulin in the United States by 2024, to help diabetic patients struggling with high prices for the life-sustaining medicine.
